Patent Litigation Settlements Should Be Filed With FDA, FTC Says
Executive Summary
FDA's 180-day ANDA exclusivity rule should require patent litigation settlements between branded companies and ANDA applicants to be filed with FDA, the Federal Trade Commission suggested in comments on FDA's proposed rule.
You may also be interested in...
Gore Pro-Generic Campaign Platform Includes Citizen Petition Restrictions
Vice President Gore is promising to address the potential for the FDA citizen petition process to be used to delay generic drug approvals if he is elected President.
Gore Pro-Generic Campaign Platform Includes Citizen Petition Restrictions
Vice President Gore is promising to address the potential for the FDA citizen petition process to be used to delay generic drug approvals if he is elected President.
ANDA Reformulations Should Not Result In Loss Of 180-Day Exclusivity - Andrx
Reformulation of a product under ANDA review should not result in the loss of 180-day exclusivity eligibility, Andrx argued in Oct. 5 comments to FDA's 180-day generic exclusivity proposed rule.